BeiGene's BTK inhibitor fails to beat market leader Imbruvica in key head-to-head study

Natalie Grover

Reporter

BeiGene’s quest to develop a superior BTK inhibitor hit a major roadblock on Monday as the company conceded that the drug failed a keenly anticipated …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

BeiGene's BTK inhibitor fails to beat market leader Imbruvica in key head-to-head study

Natalie Grover

Reporter

Sign up to read this article for free.

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Bristol Myers sues the federal government over 340B, following other drugmakers

BeiGene's BTK in­hibitor fails to beat mar­ket leader Im­bru­vi­ca in key head-to-head study

Natalie Grover

Reporter

Sign up to read this article for free.

more like this

Apogee tar­gets Dupix­ent head-to-head next year as it out­lines broad pipeline plans

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take blue­bird's Skysona gene ther­a­py

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

Bris­tol My­ers sues the fed­er­al gov­ern­ment over 340B, fol­low­ing oth­er drug­mak­ers

BeiGene's BTK inhibitor fails to beat market leader Imbruvica in key head-to-head study

Apogee targets Dupixent head-to-head next year as it outlines broad pipeline plans

Novartis to cut 139 jobs in NJ as part of commercial refocus

FDA is looking into hematology risks after patients take bluebird's Skysona gene therapy

Applied Therapeutics' rare disease drug gets a CRL

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

Bristol Myers sues the federal government over 340B, following other drugmakers